Previous Issue
Volume 38, IOCD 2025
 
 
msf-logo

Journal Browser

Journal Browser

Med. Sci. Forum, 2025, IKCSEU 2025

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Number of Papers: 1
Order results
Result details
Select all
Export citation of selected articles as:

Other

170 KB  
Proceeding Paper
Shaping AI-Based Decision Support in Kidney Cancer: Multidisciplinary Consensus from the IKCSEU25 ART Think Tank
by Ignacio Duran and Jesus Garcia-Donas
Med. Sci. Forum 2025, 39(1), 1; https://doi.org/10.3390/msf2025039001 - 6 Nov 2025
Abstract
Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) project is a Spanish, multi-institutional initiative aimed at developing a dynamic, [...] Read more.
Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) project is a Spanish, multi-institutional initiative aimed at developing a dynamic, transcriptomics-based AI model to guide systemic treatment decisions for patients with metastatic RCC (mRCC). Objective: The aim of this paper is to present the rationale, methodology, and early implementation challenges of the ART project, as discussed during a dedicated Think Tank session at the 2025 International Kidney Cancer Symposium Europe (IKCSEU25), and to gather expert insights on its clinical and regulatory viability. Design, Setting, and Participants: The ART project includes three phases: (1) retrospective algorithm training using clinical and transcriptomic data from completed trials; (2) a prospective, non-interventional study collecting multi-omic and clinical data from 500 patients across 30 centers; and (3) a future comparative analysis of ART-guided versus standard clinical decisions. The AI model is designed to evolve continuously through ongoing data integration. Results and Limitations: Experts underscored the importance of integrating multimodal data—including circulating biomarkers and immune profiling—while expressing concerns about the reliance on short-term endpoints. Key barriers identified included data harmonization, external validation, and regulatory uncertainty regarding adaptive algorithms. The absence of a clear approval pathway for non-static clinical decision support systems also poses a challenge. Despite limited initial funding, the ART platform has generated strong institutional engagement and may serve as a scalable model for clinician-oriented AI tools. Conclusions: The ART project represents an innovative approach to AI-driven personalization of kidney cancer treatment. Expert feedback from IKCSEU25 highlighted the scientific robustness of the initiative, while also emphasizing the need for broader validation, regulatory clarity, and the use of clinically meaningful endpoints to support real-world implementation. Patient Summary: Experts reviewed a new AI-based tool being developed in Spain to help doctors choose the best treatments for kidney cancer. The tool shows promise but needs further testing and must meet regulatory standards before it can be used in routine clinical care. Full article
Previous Issue
Back to TopTop